Modality
ADC
MOA
WRNi
Target
Tau
Pathway
PI3K/AKT
Atopic Derm
Development Pipeline
Preclinical
~Jul 2022
→ ~Oct 2023
Phase 1
Jan 2024
→ Jan 2029
Phase 1Current
NCT07610609
642 pts·Atopic Derm
2024-01→2029-01·Completed
642 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-232.8y awayInterim· Atopic Derm
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P1
Complet…
Catalysts
Interim
2029-01-23 · 2.8y away
Atopic Derm
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07610609 | Phase 1 | Atopic Derm | Completed | 642 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |